Unique ID issued by UMIN | UMIN000022604 |
---|---|
Receipt number | R000026029 |
Scientific Title | Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy. |
Date of disclosure of the study information | 2016/06/04 |
Last modified on | 2020/02/13 20:44:38 |
Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Impact of evelocumab in heterozygous familial hypercholesterolemia under LDL-apheresis.
Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Impact of evelocumab in heterozygous familial hypercholesterolemia under LDL-apheresis.
Japan |
Heterozygous familial hypercholesterolemia
Cardiology | Endocrinology and Metabolism |
Others
YES
To investigate the safety and the changes of lipid parameters after the introduction of evolocumab in the patients with heterozygous familial hypercholesterolemia under LDL-apheresis.
Safety,Efficacy
Comparison of the time constant average levels of LDL-C and apoB during LDL-apheresis and those under evolocumab thereapy.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Subcutaneous injection of evolocumab
20 | years-old | < |
100 | years-old | >= |
Male and Female
Heterozygous familial hypercholesterolemic patients under LDL-apheresis therapy and stable lipid-lowering therapy including statins, ezetimibe, fibrates, resin, probucol, EPA, niacin, and vitamin E
Myocardial infarction or unstable angina within 8 weeks
Severe anemia (Hb <10g/dL)
Allergy against evolocumab
Immunosupressive therapy
Severe hepatic disorder (ASTorALT>100IU/L)
Severe renal disorder (BUN>40mg/dL or Cre>2.0mg/dL)
(Possible of) pregnancy
10
1st name | Masa-aki |
Middle name | |
Last name | Kawashiri |
Kanazawa University Hospital
Department of Cardiology
920-8641
13-1 Takara-machi, Kanazawa
076-265-2251
mk@med.kanazawa-u.ac.jp
1st name | Masa-aki |
Middle name | |
Last name | Kawashiri |
Kanazawa University Hospital
Department of Cardiology
920-8641
13-1 Takara-machi, Kanazawa
076-265-2251
mk@med.kanazawa-u.ac.jp
Kanazawa University Hospital
Kanazawa University Hospital
Self funding
Innovative Clinical Research Center, Kanazawa Univrsity
13-1 Takara-machi, Kanazawa
076-265-2048(7590)
crc.irb-knz@esct.jp
NO
2016 | Year | 06 | Month | 04 | Day |
https://www.sciencedirect.com/science/article/pii/S0021915017312820?via%3Dihub
Published
https://www.sciencedirect.com/science/article/pii/S0021915017312820?via%3Dihub
11
Compared to biweekly LDL apheresis, biweekly evolocumab injection therapy is less expensive, less invasive, less time-consuming, and more effective in reducing atherogenic lipoprotein levels without severe adverse side effects.
2020 | Year | 02 | Month | 13 | Day |
Male and female patients with heterozygous familial hypercholesterolemia under stable biweekly LDL apheresis and medical therapy.
Eleven patients with HeFH undergoing biweekly LDL apheresis were enrolled and were subsequently switched to a biweekly subcutaneous injection of 140 mg of evolocumab.
nothing
The primary endpoints were percent changes in mean LDL-C and apolipoprotein B (apoB) serum levels, which were averages of two different time point measurements, due to the switch in the treatment method.
Completed
2016 | Year | 05 | Month | 25 | Day |
2016 | Year | 06 | Month | 06 | Day |
2016 | Year | 06 | Month | 06 | Day |
2016 | Year | 09 | Month | 21 | Day |
2016 | Year | 06 | Month | 04 | Day |
2020 | Year | 02 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026029
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |